Heat made AZ's FluMist ineffective against swine flu; Diamyd begins diabetes jab trial;

> FluMist maker AstraZeneca ($AZN) blames heat for its vaccine's ineffectiveness against swine flu. Report

> Diamyd Medical has dosed the first patient in its Type 1 diabetes vaccine study. Release

> ACIP has recommended Merck's ($MRK) Gardasil 9 for females ages 9 to 26 and males ages 9 to 21. Release

> In a Phase I study, Themis Bioscience's Chikungunya vaccine candidate raised concentrations of neutralizing antibodies in three dose cohorts after one immunization. Release

> Targovax has appointed Øystein Soug as its new CFO. Release

And Finally... The CDC says flu vaccines were only 18% effective this season. Report (reg. req.)